This is a routine procedural discovery ruling with zero impact on the underlying patent merits. The 30-month stays protecting Qelbree® from generic competition run through October 2028. Monitor for claim construction rulings and summary judgment motions, which will be the first substantive events. The next material catalyst is likely a Markman hearing or trial date setting.
Price Chart
Executive Summary
Supernus won a discovery dispute in its consolidated Hatch-Waxman patent litigation defending Qelbree® (viloxazine) against 8 generic challengers. The court allowed Supernus's Chief Scientific Officer to access confidential ANDA materials as in-house designee, but denied Supernus's request to share one defendant's confidential information with other defendants without consent. This is a routine procedural ruling on a discovery confidentiality order — it does not resolve any substantive patent validity or infringement issues, and the 30-month stays through October 2028 remain in place.
Court Ruling Details
Key Facts
- Ruling is a discovery dispute order on a confidentiality order — not a merits ruling on patent validity or infringement
- Supernus won the right to have its Chief Scientific Officer serve as in-house designee to review confidential ANDA materials
- Supernus lost on cross-disclosure: cannot share one defendant's confidential info with other defendants without consent
- Six Qelbree® patents are asserted; 30-month stays run through October 2, 2028
- Qelbree® (viloxazine) is approved for ADHD; NCE exclusivity expired April 2, 2026
- Eight generic challengers are consolidated in this Hatch-Waxman litigation
Financial Impact
No financial impact — this is a procedural discovery order, not a merits ruling on patent validity or infringement. Qelbree® revenue is protected by 30-month stays through October 2028.
Risk Factors
- Generic entry risk remains if Supernus loses on patent validity or infringement at trial
- NCE exclusivity expired April 2, 2026 — only the 30-month stays protect Qelbree® now
- Multiple generic challengers increase probability of at least one prevailing on invalidity or non-infringement
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion from CourtListener.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-2eosrlu4-SUPN |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 20d ago | DEFM14A | $41.49 $42.78 | ▲ +3.11% | ▲ +3.00% | $42.60 (+2.68%) |
Aug 3, 2026 8w ago | DEFA14A / 425 | $43.25 $46.88 | ▲ +8.39% | ▲ +8.49% | $42.60 (−1.50%) |
Aug 3, 2026 8w ago | 8-K | $43.25 $46.88 | ▲ +8.39% | ▲ +8.49% | $42.60 (−1.50%) |
Aug 3, 2026 8w ago | DEFA14A / 425 | $46.00 $47.07 | ▲ +2.33% | ▲ +0.30% | $42.60 (−7.39%) |
Aug 3, 2026 8w ago | 8-K | $46.00 $47.07 | ▲ +2.33% | ▲ +0.30% | $42.60 (−7.39%) |
Aug 3, 2026 8w ago | 8-K | $46.00 $47.07 | ▲ +2.33% | ▲ +0.30% | $42.60 (−7.39%) |
Aug 3, 2026 8w ago | DEFA14A / 425 / 8-K | $46.00 $47.07 | ▲ +2.33% | ▲ +0.30% | $42.60 (−7.39%) |
Jul 22, 2026 10w ago | 8-K | $47.19 $45.61 | ▼ −3.35% | ▼ −3.82% | $42.60 (−9.73%) |
Jul 22, 2026 10w ago | Press Release | $47.19 $45.61 | ▼ −3.35% | ▼ −3.82% | $42.60 (−9.73%) |
Jul 20, 2026 10w ago | Court Ruling | $47.42 $46.20 | ▼ −2.57% | ▼ −2.15% | $42.60 (−10.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access